Genetic

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Martedì, Gennaio 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

Retrieved on: 
Martedì, Gennaio 17, 2023
Associate, Roche, Center for Epidemiologic Studies Depression Scale, MS, Genetic counseling, Molecular epidemiology, Pancreatic cancer, Medical Affairs Bureau, Economics, Ohio State University, Diagnosis, Survival, Genomics, Engineering, Roche Diagnostics, Cancer, Doctor of Philosophy, Pharmaceutical industry, Genetics, Genetic

Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.

Key Points: 
  • Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics.
  • Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University.
  • Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis.
  • Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications.

Global Protein Therapeutics Market Report 2022 to 2028 - Increase in the Cases of Cancer Across the World Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Gennaio 11, 2023
Health, Other Health, Disease, Cell, Blood, Degenerative disease, Metastasis, Coagulopathy, Neoplasm, Health, Plasma, Genetic disorder, Protein, Water, Genetic, Genetic engineering, Growth, Patient, Prevalence, Sugar, Salt, Enzyme, Antibody, Infection, Pharmaceutical industry, Vaccine, Cancer

The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.

Key Points: 
  • The Global Protein Therapeutics Market size is expected to reach $490.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
  • They can also increase the supply of a helpful protein, which helps lessen the effects of chemotherapy or sickness.
  • One of the major factors that are driving the growth of the protein therapeutics market is the expansion in the prevalence of various types of cancer all over the world.
  • A major challenge in the growth of the protein therapeutics market is the high cost of protein therapies.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Gennaio 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Retrieved on: 
Martedì, Dicembre 27, 2022
Brain damage, Education, SEC filing, ACER, Blood, OTCQB, Genetic, Food, Therapy, Federal Food, Drug, and Cosmetic Act, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, RLD, Ammonia, UCD School of Medicine, Science, NDA, Patient, Degenerative disease, Marathon, SIMD, OTC, FDA, Conference, UCD, CPS, FDCA, New Drug Application, Caregiver, Bank, Pharmaceutical industry, Medical device, Acer, Relief

NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has approved OLPRUVA™ (sodium phenylbutyrate) for oral suspension in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

Key Points: 
  • “Patients who are living with UCDs now have an alternative treatment option with OLPRUVA™, to address some of the challenges they may have with existing therapy.
  • OLPRUVA™ has been approved as an oral suspension by the FDA for the treatment of patients with UCDs.
  • Acer intends to offer Navigator by Acer Therapeutics, a suite of integrated patient support services designed to facilitate access to therapy.
  • Navigator by Acer Therapeutics is designed to assist UCD patients with support, access, education, and adherence.

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

Retrieved on: 
Martedì, Dicembre 6, 2022
Atrial fibrillation, PRS, Associate, Physician, Health, ASX, Metabolism, Cardiovascular disease, Hypertension, Degenerative disease, Science, Death, Stroke, Applied Genetic Technologies Corporation, Genetic, Genetypes, GTG, Coronary artery disease, Epidemiology, Diabetes, Metabolic disorder, Type 2 diabetes, Disease, Professor, Biobank, Risk assessment, Risk, University, UK Biobank, Medical device, Pharmaceutical industry, Toy, Medical imaging, Biostatistics

The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.

Key Points: 
  • The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.
  • The cutting-edge study design meant that the polygenic risk scores developed by GTG use just the genetic changes essential to predict risk without sacrificing predictive performance compared with polygenic risk scores that use up to 820 times the number of genetic changes.
  • GTG quantified the true effects of the polygenic risk scores in predicting disease by accounting for age and sex in the study design.
  • The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals.

FDA Grants Emergency Use Authorization for Thermo Fisher Scientific’s Monkeypox Test

Retrieved on: 
Mercoledì, Dicembre 14, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Severe acute respiratory syndrome coronavirus 2, PPD, Food, Mindful Scientific Inc., Monkeypox, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Patient, DNA, Science, Patheon, Research, PCR, Pharmaceutical Services Negotiating Committee, Polymerase chain reaction, FDA, Monkeypox virus, Applied Biosystems, COVID-19, Genetic, EUA, Health, Vaccine, Orthopoxvirus

Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.
  • Ensuring that all U.S. laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency, said Manoj Gandhi, senior medical director for Genetic Testing Solutions, Thermo Fisher Scientific.
  • In early 2020, Thermo Fisher was among the first companies to distribute an emergency use authorized assay to identify active SARS-CoV-2 infections with the TaqPath COVID-19 Combo Kit .
  • For Emergency Use Authorization Only; Rx Only
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Infectious Disease Diagnostics Global Market Report 2022: Availability of Multiple Diagnostic Tests Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Dicembre 8, 2022
AIDS, Medical Supplies, Health, Medical Devices, Infectious Diseases, Other Health, Pharmaceutical, Hospital, Infection, HIV, Syphilis, Viral, Diagnosis, Prevalence, NAT, Real-time, Pandemic, Epidemic, Microbial Culture Collection, Global Infectious Disease Epidemiology Network, Viral load, World Health Organization, Lyme disease, COVID-19, Growth, Genetic, WHO, Interaction, Competitive landscape, Health, Blood, USD, Vaccine, Immunoassay

The "Infectious Disease Diagnostics - Market Insights, Competitive Landscape and, Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infectious Disease Diagnostics - Market Insights, Competitive Landscape and, Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Infectious Disease Diagnostic Market is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to surge in prevalence of infectious diseases and growing concern regarding the incidences of pandemic and epidemics.
  • Among the noteworthy drivers of the infectious disease diagnostics market, the rising prevalence of infectious diseases turns out to be the major factor for accelerating the infectious disease diagnostics market.
  • Further, rising incidences of epidemics and pandemics across the world is going to boost the market growth for infectious disease diagnostics.

Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

Retrieved on: 
Martedì, Dicembre 6, 2022
Technology, Manufacturing, Other Technology, Other Science, Other Manufacturing, Research, Science, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Infection, PPD, Mindful Scientific Inc., Workflow, Research, Science, TaqMan, Patheon, PCR, West Pharmaceutical Services explosion, Real-time, Real-time polymerase chain reaction, Applied Biosystems, Vertically transmitted infection, Genetic, MagMax, Genetic testing, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.
  • TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens.
  • With the TrueMark Infectious Disease Research Panels, laboratories can choose either the readymade panels or create their own custom panels to suit their needs, said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific.
  • For more information on the TrueMark Infectious Disease Research Panels, please visit www.thermofisher.com/truemarkpluspanels .

2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Novembre 25, 2022
Health, Pharmaceutical, Urination, Mall of America, Headache, Kidney disease, History, Polycystic kidney disease, Genetic, Blood, PKD, Cyst, R, Urine, ROA, Discovery, Genetic disorder, Diuretic, News, Human, Therapy, Research, Disorder, Pharmaceutical industry, Surveying, Marketing

Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure.

Key Points: 
  • Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure.
  • The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.